Lung Cancer - Genetics
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with James Cox, Professor of Cardiac Surgery at the Feinberg School of Medicine at Northwestern Medicine in Chicago, Illinois, USA, and Patrick McCarthy, Executive Director...
In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had...
A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...
An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
...A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
...This interesting study compared bronchial epithelial mutation burden, the primary source of new lung cancers, among nonsmokers, former smokers, and current smokers. Smoking typically adds 1,000 to 10,000 mutations per...
This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with...
Interesting follow-up study of 208 pulmonary ground -glass opacities in 160 subjects, with a yield of three adenocardinomas.
...Park and colleagues genotyped cancer tissue for epidermal growth factor receptor (EGFR) mutations in patients with complete resection for lung adenocarcinoma who had a recurrence. Lung adenocarcinoma with EGFR gene...
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was...
This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21...
The authors studied survival in patients with multiple lung cancers and their associated genetic mutations. There was 90% discordance in driver mutations beween cancers in individual patients that was associated...
A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.
...

